The period of surgical and medical therapy In the Seventies it became evident the high incidence of post-operative recurrence after curative resection for CD (up to 75% at 1 year). The trend of treatment therefore did change dramatically as the surgeons became reluctant to operate CD patients. The medical treatment (antibiotics, corticosteroids, budesonide, immunosuppressors, mesalazine) then became the first line therapy. Surgery was mainly reserved to complications (obstruction, perforation, abscesses, fistulas) and the role of surgeon shifted from central to marginal. In this period the prevention of post-operative recurrence was considered as one of the most important issue in the management of CD. Endoscopy had proved to be the best method to detect post-operative recurrence. It was also demonstrated that the post-operative clinical course of CD could be predicted by the severity of endoscopic lesions during the first year after resection. A number of drugs (antibiotics, mesalazine, corticosteroids, 6-MP, azathioprine, metotrexate, tacrolimus) were studied by randomized clinical trials (RCTs) with the aim of preventing post-operative recurrence. However available data including meta-analysis do not show a robust protective effect for any medical therapy. anti-TNF antibody, vedolizumab a monoclonal antibody that inhibits chemotaxis from the blood to intestinal wall by selectively blocking the α4β7 integrin and ustekinumab, a fully human IgG1κ monoclonal antibody that inhibits the p40 subunit shared by the proinflammatory cytokines. These agents for the first time showed that mucosal lesions of CD may completely heal after treatment. Therefore the end points of the clinical trials completely changed. Historically patients were treated based on the reduction of clinical symptoms (CDAI). Today we understand that symptoms poorly correlate with the underlying intestinal inflammation. Other more objective disease activity parameters (CRP, faecal calprotectin, reduction of intestinal lesions) have been therefore introduced. "Mucosal Healing" is now the preferred primary endpoint in ongoing trials. The combination of symptoms remission and endoscopic remission is called "deep remission". However it must be taken into consideration that fibro-stenotic lesions are irreversible and no treatment strategies are available. Individualizing therapy to optimize treatment is possible by stratifying patients at low and high risk. Patients with age > 30 years, limited anatomic involvement, no peri-anal disease, stricturing or fistula and no previous surgery were considered at low risk. Patients with age < 30 years, extensive anatomic involvement, peri-anal disease, stricturing/fistula and previous surgery were considered at high risk. The emergency of biological therapy in the treatment of CD has led to a clinical debate about so called "stepup" versus "top down" strategy.
Step up refers to the classic therapeutic approach, namely progressive intensification of treatment as disease severity increase. Treatment starts with corticosteroids/budesonide, moving to immunosuppressors (6-MP, AZT, MXT) and eventually to biologics when the response is poor. Top -down refers to the early introduction of biological agents and eventually go down to immunosuppressors when the response is positive. However, although the existing guidelines recommend to follow the stratification of patients risk to select the best treatment strategy, most of the gastroenterologists use in any case anti TNF-α as first-line treatment and switch to other biologics when anti TNF-α fails. However it should be taken into consideration that epidemiological studies have shown that over 50% of CD patients have a mild disease over time and will never require aggressive therapies. The indiscriminate use of top-down strategy would therefore represent an over treatment for most of CD patients. Toxicity and high cost of biologics are also drawbacks for their indiscriminate use. With the spreading of biological therapies, surgery has become obsolete. However it is common experience that medical therapy (biological included) is poorly effective in "stricturing" or "penetrating" CD and that these patients still undergo surgery in 60-70% of the cases within 10 years of diagnosis. Results of recent trials with anti TNF-α showed that mucosal healing in CD was associated with a higher clinical response, reduced hospitalization rates and need for surgery. However, recent data from population-based cohorts studies showed that the rate of surgery within 5 years of diagnosis was of the same order in pre-and post-anti TNF-α era. Surgery therefore should not be dismissed as the end of the road after all medical options have failed, but should be considered a significant component of the entire management strategy of CD. The early surgery in the presence of obstruction, abscess-fistula or lesions limited to a short ileal segment maintains a primary role. Very good results have been also reported by mini-invasive laparoscopic surgery. It appears that the advent of biological agents has deeply changed the clinical practice and the therapeutic algorithms in CD. The possibility of inducing mucosal healing hold out much hope of changing the natural history of CD as it occurred in rheumatoid arthritis, psoriasis arthritis and ankylosing spondylitis. However, it is not yet demonstrated that biological therapies can influence the long-term natural history of CD. Despite the great therapeutic advances in CD no drug prevents, nor reverses established strictures. In the last few years, however, a new era seems to arise. In fact, a recent study (POCER) demonstrated that a combination of surgery and biological therapies, could improve the outcomes of these patients, by early treatment the post-operative recurrence with anti-TNF drugs. Perhaps a new battle begun and we look forward for long-term results. To conclude, though the advent of the biological therapies has deeply changed the conventional therapy of CD, this fascinating story is not over yet and the best management still results from the tight collaboration of the gastroenterologist and surgeon expert in IBD. We ultimately need to have cost utility analyses to help us select the most appropriate medical or surgical therapies both for the patients and the society.
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